Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Integrin
Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Pipeline Review, H1
2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

The report ‘Integrin Beta 7 – Pipeline Review, H1 2019’ outlays
comprehensive information on the Integrin Beta 7 (Gut Homing Receptor
Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by
indications, stage of development, mechanism of action (MoA), route of
administration (RoA) and molecule type; that are being developed by
Companies/Universities.

It also reviews key players involved in Integrin Beta 7 (Gut Homing
Receptor Beta Subunit or ITGB7) targeted therapeutics development with
respective active and dormant or discontinued projects. Currently, The
molecules developed by companies in Pre-Registration, Phase III, Phase
I, Preclinical and Discovery stages are 1, 1, 1, 1 and 3 respectively.

Report covers products from therapy areas Gastrointestinal, Immunology,
Infectious Disease and Undisclosed which include indications
Inflammatory Bowel Disease, Ulcerative Colitis, Crohn’s Disease
(Regional Enteritis), Graft Versus Host Disease (GVHD), Human
Immunodeficiency Virus (HIV) Infections (AIDS) and Unspecified.

Scope

• The report provides a snapshot of the global therapeutic landscape for
  Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
• The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit
  or ITGB7) targeted therapeutics under development by companies and
  universities/research institutes based on information derived from
  company and industry-specific sources
• The report covers pipeline products based on various stages of
  development ranging from pre-registration till discovery and
  undisclosed stages
• The report features descriptive drug profiles for the pipeline
  products which includes, product description, descriptive MoA, R&D
  brief, licensing and collaboration details & other developmental
  activities
• The report reviews key players involved in Integrin Beta 7 (Gut Homing
  Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all
  their major and minor projects
• The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit
  or ITGB7) targeted therapeutics based on mechanism of action (MoA),
  route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline
  projects
• The report reviews latest news and deals related to Integrin Beta 7
  (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons to Buy

• Gain strategically significant competitor information, analysis, and
  insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for
  Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
• Identify the use of drugs for target identification and drug
  repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of
  leading companies
• Plan mergers and acquisitions effectively by identifying key players
  and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding
  Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
  development landscape
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope

Key Topics Covered:

1. Introduction
2. Report Coverage
3. Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Overview
4. Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) –
   Therapeutics Development
5. Products under Development by Stage of Development
6. Products under Development by Therapy Area
7. Products under Development by Indication
8. Products under Development by Companies
9. Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) –
   Therapeutics Assessment
10. Assessment by Mechanism of Action
11. Assessment by Route of Administration
12. Assessment by Molecule Type

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Companies
Involved in Therapeutics Development

• C4X Discovery Holdings PLC
• Genentech Inc
• Morphic Therapeutic Inc
• Protagonist Therapeutics Inc
• Takeda Pharmaceutical Co Ltd

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Drug
Profiles

• ET-3764 – Drug Profile
• etrolizumab – Drug Profile
• PN-943 – Drug Profile
• Small Molecule to Antagonize Integrin Alpha4 and Beta7 for
  Inflammatory Bowel Disease – Drug Profile
• Small Molecule to Antagonize ITGA4 and ITGB7 for Unspecified
  Indication – Drug Profile
• Small Molecules to Antagonize Integrin Alpha4 and Beta7 for
  Inflammatory Bowel Disease – Drug Profile
• vedolizumab – Drug Profile

Featured News & Press Releases

• Mar 11, 2019: Takeda’s Entyvio achieves superior remission than Humira
  in ulcerative colitis
• Mar 11, 2019: Takeda Canada announces positive results for ENTYVIO
  (vedolizumab) vs. Humira (adalimumab) in first IBD study to compare
  biological agents head-to-head
• Dec 17, 2018: Entyvio post-marketing safety data consistent with
  previous clinical trials
• Dec 13, 2018: Protagonist Therapeutics initiates phase 1 trial of
  oral, gut-restricted, alpha-4-beta-7 integrin antagonist PN-10943
• Nov 27, 2018: Protagonist Therapeutics announces new development
  candidate PN-10943 for the treatment of inflammatory bowel disease
• Nov 07, 2018: Takeda announces launch of Entyvio (vedolizumab) for the
  treatment of adult patients with moderately to severely active
  ulcerative colitis in Japan
• Oct 27, 2018: Takeda comments on ongoing Phase 1 review by the
  European Commission of the proposed acquisition of Shire
• Oct 22, 2018: Investigational subcutaneous formulation of Vedolizumab
  achieves and maintains clinical remission and mucosal healing at Week
  52 in patients with moderately to severely active Ulcerative Colitis
• Oct 08, 2018: New real-world data analyses support the long-term use
  of Entyvio (Vedolizumab) in bio-nave patients for the treatment of
  moderate to severe ulcerative colitis or crohn’s disease
• Jul 19, 2018: Takeda reports positive top-line outcomes from VISIBLE 1
  trial
• Jul 18, 2018: Takeda Submits an Application for a New Indication of
  Entyvio (vedolizumab) for the Treatment of Adult Patients with
  Moderately to Severely Active Crohn’s Disease in Japan
• Jul 02, 2018: Takeda Obtains New Drug Application Approval for Entyvio
  (vedolizumab) for the Treatment of Ulcerative Colitis in Japan
• Jun 05, 2018: Analysis of real-world safety data shows gut-selective
  ENTYVIO (vedolizumab) had fewer serious infections and adverse events
  than those on systemic TNFa-antagonist therapy in ulcerative colitis
  and Crohn’s disease patients
• Jun 03, 2018: Takeda Highlights Favorable Safety Profile of Entyvio
  (vedolizumab) Through Comparative Real-World Data Versus
  TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn’s Disease
• May 15, 2018: Bio-Rad Introduces Anti-Vedolizumab Antibodies

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/6eb64e

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs